Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 2/20 | 0.67 |
| ▸ | ESR1 | P03372 | 6/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | FYN | P06241 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL503526 | 1.00 | BLM (0.67) | BLMESR1ESR2MEN1KMT2A | |
| SCHEMBL503525 | 1.00 | BLM (0.67) | BLMESR1ESR2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL540242 | 0.98 | BLM (0.65) | BLMESR1ESR2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL540244 | 0.98 | BLM (0.65) | BLMESR1ESR2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL1322060 | 0.98 | BLM (0.65) | BLMESR1ESR2MEN1KMT2A | |
| SCHEMBL180210 | 0.85 | BLM (0.47) | BLMMEN1KMT2AKDM4EUSP2 | |
| SCHEMBL3647847 | 0.85 | BLM (0.65) | BLMESR1ESR2MEN1KMT2A | |
| SCHEMBL31195654 | 0.85 | BLM (0.47) | BLMMEN1KMT2AKDM4EUSP2 | |
| SCHEMBL180265 | 0.85 | BLM (0.47) | BLMMEN1KMT2AKDM4EUSP2 | |
| SCHEMBL4610735 | 0.85 | BLM (0.65) | BLMESR1ESR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112867705-B | Opioid receptor modulators and products and methods related thereto | 埃皮欧黛公司 | 2024-08-20 | — | — | CN | disclosed |
| EP-3774722-B1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | EPIODYNE INC (US) | 2024-07-24 | — | — | EP | disclosed |
| US-11352316-B2 | Opioid receptor modulators and products and methods related thereto | EPIODYNE, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| CN-114599352-A | alpha-methyl-DL-tyrosine alkyl esters for the treatment of cancer | 迪美公司 | 2022-06-07 | — | — | CN | disclosed |
| WO-2021076723-A1 | ALKYLESTERS OF ALPHA-METHYL-DL-TYROSINE FOR USE IN TREATING CANCER | TYME, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
| US-20210106549-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS | TYME, INC. | 2021-04-15 | — | — | US | disclosed |
| EP-2262364-B1 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | VTV THERAPEUTICS LLC (US) | 2016-03-02 | — | — | EP | disclosed |
| US-9175003-B2 | Substituted azoanthracene derivatives and intermediates for preparation thereof | VTV THERAPEUTICS LLC (US) | 2015-11-03 | — | — | US | disclosed |
| WO-2015152128-A1 | AMINO ACID PRECURSOR, AMINO ACID, AND PRODUCTION METHOD FOR AMINO ACID, AND PET DIAGNOSTIC TRACER USING AMINO ACID | 長瀬産業株式会社 | 2015-10-08 | — | — | WO | disclosed |
| EP-2413693-B1 | SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | VTV THERAPEUTICS LLC (US) | 2015-09-09 | — | — | EP | disclosed |
| CN-1199049-A | Novel dipeptide derivatives and sweetening agents | AJINOMOTO KK (JP) | 1998-11-18 | — | — | CN | disclosed |
| US-5331006-A | Cholecystokinin, antisecretory agents | WARNER-LAMBERT COMPANY (US) | 1994-07-19 | — | — | US | disclosed |
| WO-1992004025-A1 | AMINO ACID ANALOGS AS CCK ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1992-03-19 | — | — | WO | disclosed |
| WO-1992001667-A1 | RENAL-SELECTIVE PRODRUGS FOR CONTROL OF RENAL SYMPATHETIC NERVE ACTIVITY IN THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1992-02-06 | — | — | WO | disclosed |
| WO-1991001724-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1991-02-21 | — | — | WO | disclosed |
| US-4138484-A | CHLORPROMAZINE OR THORIDAZINE WITH G-HYDROXYBUTYROLACTONE | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1979-02-06 | — | — | US | disclosed |
| US-4134991-A | PARKINSON*S DISEASE, CARDIOVASCULAR DISORDERS, NEUROLEPTIC AGENTS | SYNTHELABO (FR) | 1979-01-16 | — | — | US | disclosed |
| US-4129652-A | CHLORPROMAZINE OR THIORIDAZINE AND 5-ETHYL-5-PHENYL-2-PYRROLIDONE OR 1-HYDROXY-3-AMINO-2-PYRROLIDONE OR SALTS | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1978-12-12 | — | — | US | disclosed |
| US-4084000-A | NEUROLEPTIC, GAMMA-AMINOBUTYRIC ACID DERIVATIVES | NELSON RESEARCH AND DEVELOPMENT COMPANY (US) | 1978-04-11 | — | — | US | disclosed |
| US-3978216-A | AMINOOXYACETIC ACID | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1976-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352316-B2 | Opioid receptor modulators and products and methods related thereto | OPRM1, OPRD1, OPRK1 | BLM 4370/4885ESR1 397/4885ESR2 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.